Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study

Remyelination is extensive in a subset of multiple sclerosis patients

Peter Patrikios, Christine Stadelmann, Alexandra Kutzelnigg et al. · Brain · 2006 · 799 citations · Full text

Life Sciences, Neurology, Neuroscience +10

Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain

Klaus Schmierer, Francesco Scaravilli, Daniel R. Altmann et al. · Annals of Neurology · 2004 · 777 citations

Medicine, Neurology, Neuroscience +17

Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study

Peter Connick, Madhan Kolappan, Charles Crawley et al. · The Lancet Neurology · 2012 · 606 citations · Full text

Life Sciences, Neurology, Neuroscience +15

Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis

Feng Mei, Stephen P.J. Fancy, Yun‐An Shen et al. · Nature Medicine · 2014 · 590 citations

Engineering, Neurology, Neuroscience +11

Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial

Ari Green, Jeffrey M. Gelfand, Bruce Cree et al. · The Lancet · 2017 · 577 citations · Full text

Life Sciences, Neurology, Neuroscience +13